Logo

Perlegen and Bristol-Myers Squibb in Pharmacogenomics Deal

Dec 19, 2002

NEW YORK, Dec. 19-Perlegen Sciences will identify pharmacogenomic markers for Bristol-Myers Squibb, the company said today.

 

In the partnership, the companies will use Perlegen's chip-based resequencing technology to scan the genomes of hundreds of participants in clinical trials for markers associated with drug response.

 

Perlegen will apply its collection of more than 1.5 million SNPs to the data in order to identify new markers.

 

Through the deal, Perlegen will get research funding, milestone payments, royalties, and rights to certain diagnostics.

 

Financial details of the partnership were not disclosed.

 

Perlegen is an Affymetrix spinoff based in Mountain View, Calif.

Breaking News
The Scan

Driving Malaria-Carrying Mosquitoes Down

Researchers from the UK and Italy have tested a gene drive for mosquitoes to limit the spread of malaria, NPR reports.

Office Space to Lab Space

The New York Times writes that some empty office spaces are transforming into lab spaces.

Prion Pause to Investigate

Science reports that a moratorium on prion research has been imposed at French public research institutions.

Genome Research Papers on Gut Microbe Antibiotic Response, Single-Cell RNA-Seq Clues to Metabolism, More

In Genome Research this week: gut microbial response to antibiotic treatment, approach to gauge metabolic features from single-cell RNA sequencing, and more.